Charles River Laboratories
CRL
$295.19
+1.28%
Charles River Laboratories International, Inc. is a leading provider of drug discovery, non-clinical development, and manufacturing support services, operating primarily in the pharmaceutical and biotechnology industry. Founded in 1947, the company is a market leader in research models and services, offering animal models and preclinical testing that are essential for drug development. Currently, the stock is attracting significant investor attention due to a sharp rally driven by strong demand for its services, a rebound in biotech funding, and strategic initiatives to expand its manufacturing support segment. The company is also navigating a period of margin pressure and recent acquisitions, which are central to the ongoing debate about its growth trajectory and profitability.…
CRL
Charles River Laboratories
$295.19
Investment Opinion: Should I buy CRL Today?
Based on the analysis, CRL is rated a Hold. The stock has strong momentum and a favorable industry outlook, but the recent financial performance is weak, with a net loss and margin contraction. The average analyst target of $281.00 implies a -4.8% downside from the current price, suggesting limited upside. The consensus recommendation is 'Buy', but the wide target range (low $145, high $318) indicates high uncertainty.
Sign up to view all
CRL 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between positive momentum and weak fundamentals. The stock's strong technical performance and analyst support are offset by margin pressure and modest growth. To upgrade to bullish, we would need to see evidence of margin recovery and accelerating revenue growth. Conversely, a downgrade to bearish would be warranted if the company reports another loss or if biotech funding deteriorates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Charles River Laboratories's 12-month outlook, with a consensus price target around $281.00 and implied upside of -4.8% versus the current price.
Average Target
$281.00
0 analysts
Implied Upside
-4.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$145 - $318
Analyst target range
The stock is covered by 14 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.75 (where 1 is Strong Buy and 5 is Sell). The average price target is $281.00, implying a -4.8% downside from the current price of $295.19. The target range is $145.00 to $318.00, with the low target suggesting a potential 50.9% downside, while the high target offers 7.7% upside. Recent ratings actions have been mostly positive, with upgrades from Morgan Stanley (to Overweight) and CLSA (to Outperform), but the wide spread between low and high targets indicates significant uncertainty about the company's future performance.
Bulls vs Bears: CRL Investment Factors
CRL presents a mixed picture: strong momentum and a favorable industry backdrop are offset by weak recent financials and a rich valuation. The bull case rests on the biotech funding rebound and expected earnings recovery, while the bear case highlights margin erosion and sluggish growth. Currently, the bull case has slightly stronger evidence given the stock's momentum and analyst support, but the key tension is whether the company can translate its strategic initiatives into improved profitability. If margins recover and revenue growth accelerates, the stock could justify its valuation; otherwise, a correction toward the average target is likely.
Bullish
- Strong momentum with 91% 1-year gain: CRL has surged 91.0% over the past year and 74.8% in six months, currently trading at $295.19, near its 52-week high of $299.32. This reflects robust investor confidence and a strong uptrend, supported by a 34.97% one-month gain that outperformed the S&P 500 by 32.5 percentage points.
- Undervalued on forward earnings and sales: The forward P/E of 23.27x is reasonable for a company expected to earn $16.46 per share next year, and the price-to-sales ratio of 2.51x is below the industry average of 3.5x. The PEG ratio of 0.045 suggests the stock is undervalued relative to its expected growth, though this relies on forward estimates.
- Analyst consensus is Buy with upside potential: With 14 analysts, the consensus is 'Buy' (mean rating 1.75), and the average price target is $281.00, implying a modest -4.8% downside from the current price. However, the high target of $318.00 offers 7.7% upside, and recent upgrades from Morgan Stanley and CLSA signal positive sentiment.
- Rebound in biotech funding driving demand: The company is benefiting from a sharp rally in biotech funding, which is increasing demand for its drug discovery and preclinical services. This macro tailwind is a key driver of the recent stock surge and supports future revenue growth.
Bearish
- Recent quarter showed net loss and margin contraction: In Q1 2026, CRL reported a net loss of -$14.84 million (EPS -$0.30) versus a profit of $25.47 million (EPS $0.50) a year ago. Gross margin fell to 28.05% from 32.28%, and net margin turned negative at -1.49%, indicating significant margin pressure.
- Revenue growth is sluggish at just 1.18%: Q1 2026 revenue grew only 1.18% year-over-year to $995.83 million, a deceleration from prior quarters. This modest growth may not justify the stock's high valuation, especially if the biotech funding rebound fades.
- High debt levels and negative ROE: Debt-to-equity is 0.97, indicating substantial leverage, and return on equity is -4.56%, reflecting poor profitability. The company's interest expense of $26.74 million in Q1 2026 adds to financial risk, especially if earnings remain weak.
- Stock trades near 52-week high, limiting upside: At $295.19, the stock is 98.5% of its 52-week range, and the average analyst target of $281.00 implies a -4.8% downside. This suggests the market has already priced in much of the good news, leaving limited room for further gains.
CRL Technical Analysis
The stock is in a powerful uptrend, with a 1-year price change of +91.0% and a 6-month change of +74.8%. The current price of $295.19 sits at 98.5% of its 52-week range (low $144.26, high $299.32), indicating that the stock is trading near its highs, reflecting strong momentum and investor optimism. This positioning suggests the market is rewarding the company's recent performance, though it also raises concerns about potential overextension in the short term.
Beta
1.38
1.38x market volatility
Max Drawdown
-33.9%
Largest decline past year
52-Week Range
$144-$299
Price range past year
Annual Return
+91.0%
Cumulative gain past year
| Period | CRL Return | S&P 500 |
|---|---|---|
| 1m | +35.0% | +3.6% |
| 3m | +84.1% | +2.7% |
| 6m | +74.8% | +11.4% |
| 1y | +91.0% | +18.7% |
| ytd | +45.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRL Fundamental Analysis
Revenue for the most recent quarter (Q1 2026) was $995.83 million, up 1.18% year-over-year, showing modest growth. However, the company reported a net loss of -$14.84 million, with EPS of -$0.30, a sharp decline from the prior year's profit of $25.47 million (EPS $0.50). The gross margin contracted to 28.05% from 32.28% a year ago, indicating margin pressure. The company's profitability has been volatile, with a net margin of -1.49% in Q1 2026, compared to 2.59% in Q1 2025, reflecting challenges in cost management and acquisition-related expenses.
Quarterly Revenue
$995830000.0B
2026-03
Revenue YoY Growth
+1.2%
YoY Comparison
Gross Margin
28.1%
Latest Quarter
Free Cash Flow
$391290000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRL Overvalued?
Given the negative trailing net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 2.51x, which is below the industry average of 3.5x, suggesting a discount. The forward PE of 23.27x implies the market expects a return to profitability, with estimated EPS of $16.46 for the next fiscal year. The PEG ratio of 0.045 is extremely low, indicating that the stock may be undervalued relative to its expected growth, though this is based on forward estimates that carry uncertainty.
PE
-70.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, CRL faces significant risks from its high debt load (debt-to-equity of 0.97) and negative profitability. The company reported a net loss of -$14.84 million in Q1 2026, with a net margin of -1.49%, and its return on equity is -4.56%. Interest expenses of $26.74 million per quarter add pressure, and if the company cannot improve margins, it may struggle to service its debt. Additionally, revenue growth is only 1.18% year-over-year, which may not be sufficient to support the current valuation, especially if the biotech funding environment weakens.
FAQ
The key risks include: 1) Financial risk from high debt (debt-to-equity of 0.97) and negative profitability, which could lead to liquidity issues if earnings don't recover. 2) Market risk from high beta (1.376), making the stock susceptible to market downturns. 3) Competitive risk from other CROs and in-house R&D by pharma companies. 4) Macro risk from a slowdown in biotech funding, which would reduce demand for CRL's services. The most severe risk is a prolonged margin contraction, which could push the stock toward the 52-week low of $144.26, a -51% downside.
The 12-month forecast is mixed. The base case (50% probability) sees the stock trading around the average analyst target of $281, implying a -4.8% downside. The bull case (30% probability) could push it to $318 or higher if the biotech rebound accelerates and margins improve. The bear case (20% probability) could see it fall to $145 if earnings disappoint and funding dries up. The most likely scenario is the base case, assuming the company returns to profitability and maintains modest growth.
CRL's valuation is mixed. On a price-to-sales basis, it trades at 2.51x, below the industry average of 3.5x, suggesting it is undervalued relative to peers. However, its forward P/E of 23.27x is not cheap, and the PEG ratio of 0.045 is extremely low, indicating the market expects high growth. Given the recent net loss, the stock is not cheap on trailing earnings, but if the company meets forward EPS estimates of $16.46, the valuation could be justified. Overall, it appears fairly valued to slightly undervalued based on forward estimates.
CRL is a good buy for investors who are optimistic about the biotech sector's recovery and believe the company can improve its margins. The stock has strong momentum, with a 91% gain over the past year, and analysts have a 'Buy' consensus. However, the average price target of $281 implies a -4.8% downside from the current price, so the risk-reward is not compelling for new entries. It may be better to wait for a pullback or for evidence of margin improvement before buying.
CRL is more suitable for long-term investors who can tolerate volatility and believe in the secular growth of drug development services. The stock has a beta of 1.376, indicating high short-term volatility, and its recent 91% gain suggests it may be overextended in the short term. For long-term investors, the company's leadership in essential services and the expected earnings recovery could provide solid returns over 3-5 years. A minimum holding period of 3 years is recommended to ride out cyclical downturns and allow the company to execute its growth strategy.